EMA Authorised: Zolgensma (onasemnogene abeparvovec) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy under conditional, orphan designation, with Novartis Europharm Limited as th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Status: Authorised. Therapeutic area: Muscular Atrophy, Spinal. MAH: Novartis Europharm Limited. Decision date: 27/08/2025. Conditional approval. Orphan medicine